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Abstract
Background—Late–onset Alzheimer's disease (AD) is heritable with 20 genes showing genome 
wide association in the International Genomics of Alzheimer's Project (IGAP). To identify the 
biology underlying the disease we extended these genetic data in a pathway analysis.
Methods—The ALIGATOR and GSEA algorithms were used in the IGAP data to identify 
associated functional pathways and correlated gene expression networks in human brain.
Results—ALIGATOR identified an excess of curated biological pathways showing enrichment 
of association. Enriched areas of biology included the immune response (p = 3.27×10-12 after 
multiple testing correction for pathways), regulation of endocytosis (p = 1.31×10-11), cholesterol 
transport (p = 2.96 × 10-9) and proteasome-ubiquitin activity (p = 1.34×10-6). Correlated gene 
expression analysis identified four significant network modules, all related to the immune 
response (corrected p 0.002 – 0.05).
Conclusions—The immune response, regulation of endocytosis, cholesterol transport and 
protein ubiquitination represent prime targets for AD therapeutics.
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Background
Alzheimer's disease (AD) affects over 5M Americans: one in eight over the age of 65 and 
represents >60% of the 6M dementia cases in Europe[1-3]. It is the commonest cause of 
dementia and imposes a large socioeconomic burden on individuals, their families and 
society. Prevalence is estimated to treble by 2050: thus understanding the mechanisms 
underlying this disease and developing treatments for it are essential. This study utilises the 
largest GWAS sample yet assembled for late-onset AD[4], and is the first to combine 
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GWAS and expression data in a systematic search for the biological pathways underlying 
the genetic susceptibility to this disorder.
Much of our current understanding of the mechanisms that contribute to AD derives from 
the genetics of Mendelian forms of the disease: mutations in APP, PSEN1 and PSEN2 cause 
early onset forms of AD and underpin the amyloid cascade hypothesis[5]. While amyloid 
deposition is diagnostic of AD, its aetiological contribution to the majority of common late 
onset AD (LOAD) is unclear and therapeutic strategies addressing the amyloid cascade 
hypothesis have been unsuccessful[6]. Therefore other therapeutic avenues must be 
identified and targeted.
LOAD is genetically complex with 56-79% heritability[7]. In the Genetic and 
Environmental Risk in Alzheimer's Disease (GERAD) dataset[8] approximately 20% of the 
total trait variance was accounted for by SNPs on the GWAS chip outside the APOE 
region[9], with the e4 allele of the apolipoprotein E gene[10] accounting for a similar 
amount[9, 11]. However, a substantial proportion of the genetic variance of late-onset AD is 
not accounted for by the 20 susceptibility genes currently identified[11]. The remaining 
genetic variance is likely to be due both to susceptibility genes of small effect which current 
sample sizes are insufficient to detect, and to rare variants, such as the coding variants in 
TREM2[12], that are poorly tagged by common variants in GWAS panels. In addition, 
individual genome-wide signficant genes identified in such studies may themselves not form 
good therapeutic targets and the areas of biology that they highlight may only give a partial 
view of the potential therapeutic landscape. In order to gain the maximum useful 
information about causative pathways that may underpin LOAD and be prime targets for 
pharmaceutical intervention we performed a robust pathway and integrated gene expression 
analysis using the largest available GWAS for AD[4].
Methods
Samples and genetic data
The sample comprised 17,008 AD cases and 37,646 control subjects in the primary GWAS 
analysis, with 8,752 AD cases and 11,312 control subjects in the replication/extension 
sample and is described in detail elsewhere[4]. Only selected SNPs were genotyped in the 
replication/extension sample (see Online Methods).
Pathway analyses—We explored whether particular biological pathways were enriched 
for genetic associations[13-14]in the IGAP data[4]. We used ALIGATOR[13-14], to test 
whether genes containing signals below the genome-wide significance threshold contribute 
to a pathway signal. ALIGATOR defines significant genes as having a best single-SNP p-
value less than a pre-set threshold. The resulting list of significant genes is compared to 
replicate gene sets generated by sampling SNPs randomly (thereby correcting for gene size). 
The method also controls for linkage disequilibrium between genes, and multiple testing of 
non-independent pathways (see Online Methods). Brown's method [15] was used to test 
pathway enrichment in the replication data. This method combines multiple SNPs together, 
explicitly correcting for both LD between SNPs and number of SNPs per gene (see Online 
Methods). Thus, correction for gene size was applied at both stages of the analysis. We 
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interrogated the externally curated gene ontology (GO), KEGG and MSigDB functional 
pathway collections (see Online Methods).
Expression correlation analyses—We used the expression data from Gibbs et al.[16] 
and performed weighted gene correlation network analysis (WGCNA) using the WGCNA 
package[17], separately on each tissue type to identify clusters of highly correlated genes 
called ‘modules’. These modules were then tested for enrichment of GWA association signal 
in ALIGATOR.
Results
The sub-genome-wide significant variation in the IGAP data contains genetic signal, 
manifest by a significant excess of SNPs at all significance threshold up to p = 0.05 
(Supplementary Table 1). This signal is unlikely to be due to uncorrected stratification, since 
each of the individual Caucasian GWAS samples in the IGAP meta analysis was corrected 
for ethnic variation using principal components[18].
We first identified a significant excess of biological pathways enriched for association signal 
in the IGAP data (Table 1, Supplementary Table 2). Using the most significant 18,472 SNPs 
(p < 8.32 ×10-4) from IGAP[4], covering the top 5% of genes, 177 significantly enriched 
(p<0.01) curated pathways were identified by ALIGATOR. To ensure that the excess of 
pathways was not an artifact of LD with genes of strong effect, we performed secondary 
enrichment analyses removing all genes that lay in the LD region of APOE or any of the 
genome-wide significant (GWS) genes from the IGAP[4] study. A significant excess of 
enriched pathways remained (Table 1), showing that the pathways showed significant 
enrichment independent of the “known” AD genes. Likewise, a significant excess of 
enriched pathways was observed when the p-value criterion for defining significant SNPs 
and genes was varied (Supplementary Table 3).
Many of the 177 pathways with p<0.01 in ALIGATOR are still significantly enriched after 
removing the APOE region and genes within 1Mb of a genome-wide significant SNP (Table 
2, Supplementary Table 4). They remain significantly enriched under a range of p-value 
criteria for defining significant SNPs, and are also significant under a GSEA analysis 
[19-20]. This robustness to analysis parameters and methods gives confidence that the 
enrichments observed by ALIGATOR are genuine. Of the 177 pathways significant at 
p<0.01 in the ALIGATOR analysis of the IGAP GWAS, 119 are significant (p<0.05) in the 
replication sample. This is more than expected by chance (see Online Methods), a further 
confirmation that the pathways highlighted by the ALIGATOR analysis contain genuine 
signals. Notably, pathway SNPs had significantly lower replication p-values than non-
pathway SNPs even after correcting for their p-value in the original IGAP GWAS (2-sided 
p=0.0237, see Online Methods). Thus, the pathway analyses highlighted which among a set 
of associated, but not genome-wide significant, SNPs are likely to replicate and therefore be 
enriched for true signals. To obtain the most strongly enriched pathways in the entire 
dataset, the p-values from the ALIGATOR analysis were combined with those from the 
replication study using Fisher's method and corrected for multiple testing of 9,816 pathways 
using Sidak's formula. Forty-five pathways were significant after multiple testing correction 
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(Sidak p<0.05) in the combined dataset. These pathways are shown in Table 2, grouped into 
clusters by gene membership, such that pathways with more than 40% of genes in common 
are gathered in a cluster.
This multiple testing correction may be considered conservative since it assumes that the 
pathways are independent, whereas in fact there is considerable genic overlap between them. 
Sidak-corrected p-values for the combined IGAP GWAS and replication datasets are 
therefore given in Supplementary Table 4 for all 177 pathways significant at p<0.01 in the 
ALIGATOR analysis of the IGAP GWAS. Redundant pathways (i.e. those with high genic 
overlap with other pathways) were not pruned from our analysis since it is not clear a priori 
which pathways will give the most significant enrichment and should thus be retained. 
Pruning a posteriori (i.e. by choosing the most significant pathways) will bias the 
significance of the combined discovery and replication p-values (making the correction for 
multiple testing of pathways anticonservative). The pathway clusters given in Table 2 and 
Supplementary Table 4 are intended to aid interpretation of our results in light of shared 
gene membership between pathways, by highlighting areas of biology rather than individual 
pathways.
The clusters of multiple pathways were related to the broad categories of immune response, 
regulation of endocytosis, cholesterol transport, protein ubiquitination and clathrin, with the 
first three of these being particularly strongly enriched for signal. Since one would expect 
SNPs showing strong association to be significant upon replication regardless of biology, the 
analysis was repeated removing genes containing a genome-wide significant SNP in the 
IGAP GWAS from the analysis of the replication data. From Table 2 it can be seen that the 
immune-related and ubiquitination pathways are still highly significant. Sidak-corrected p-
values for all 177 pathways significant at p<0.01 in the ALIGATOR analysis are shown in 
Supplementary Table 4. The relationship between the enriched pathways is shown by their 
shared gene membership (Figure 1). Table 3 lists genes in the clusters identified in Table 2 
that are counted as significant (best single-SNP p<8.32×10-4) in the ALIGATOR analysis of 
the IGAP GWAS and also gene-wide significant (gene-wide p<0.05) in both the IGAP 
GWAS and the replication data. P-values for all genes counted as significant in the 
ALIGATOR analysis from the 177 pathways enriched at p<0.01 are given in Supplementary 
Table 5.
In contrast to ALIGATOR, GSEA uses all genes (rather than using a threshold) and weights 
these by their significance, so may highlight different biological signals. We therefore 
performed a secondary analysis of all pathways using GSEA. Pathways significant under 
GSEA but not ALIGATOR are shown in Supplementary Table 6. Most of these pathways 
relate to areas of biology already highlighted in the ALIGATOR analysis, the exceptions 
being synapse, neuronal differentiation and calcium signalling (Supplementary Table 6). 
Genes contributing to these pathway signals that are significant in both the IGAP GWAS 
and the replication study are listed in Supplementary Table 7. Notably, these pathways 
contain large genes. In addition to the differences between ALIGATOR and GSEA 
described above, the Simes correction for gene size used by GSEA is less stringent for large 
genes than that used by ALIGATOR, thereby explaining the discrepancy in the results 
between the methods.
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In the ALIGATOR analysis 73.2% of the top 5% of genes mapped to a pathway, leaving a 
substantial minority of genes unannotated: in addition many annotated genes may possess 
other functions not currently annotated. Genes with correlated expression patterns display 
functional similarities and Zhang et al.[21] highlighted modules of co-expressed genes as 
being important in the aetiology of LOAD. Therefore, in order to overcome the annotation 
gap and access biologically related signal across the entire genome, we created modules of 
brain co-expressed genes and tested them for enrichment of association signal in the IGAP 
GWAS. The dataset we used consisted of gene expression data from four brain regions in a 
sample of approximately 150 control brains[16], and was independent from that used by 
Zhang et al.[21]. We used control individuals rather than AD cases so that correlations 
between expression levels would not be confounded by neuron loss. A weighted gene 
correlation network analysis (WGCNA)[17] gave 117 modules of co-expressed genes in 
these data (see Online Methods and Supplementary Table 8): these 117 modules were tested 
for enrichment of association signal in the IGAP GWAS using ALIGATOR. Four modules 
were found to be significantly enriched after correcting for multiple testing, and these 
enrichments were robust to varying p-value criteria and analysis methods (Supplementary 
Table 9). The four significantly enriched modules, one from each brain region, are all related 
to the immune response and have overlapping gene membership (Figure 2).
The extent to which the overlap in gene membership between these modules is related to the 
GWAS signal was investigated by examining genes that occurred in multiple modules and 
testing these for enrichment using ALIGATOR and GSEA (Supplementary Table 10). It can 
be seen that the set of 151 out of 294 genes that are present in two or more modules 
consistently showed the most significant enrichment of IGAP signal across a variety of test 
criteria. Conversely, the set of 143 genes present in only one module showed no significant 
enrichment for association signal, highlighting the utility of using multiple datasets to 
produce meaningful co-expression modules. Figure 2 shows the strongest correlations (>0.9 
in at least one brain area) between the 151 genes present in two or more modules. It can be 
seen that the TYROBP gene highlighted by Zhang et al.[21] as an important causal regulator 
is also a hub gene in this network. Pathways significantly enriched in the 151 genes present 
in two or more modules are shown in Figure 2, clustered by gene membership. Many of the 
enriched pathways are immune-related, but some are related to fatty acid metabolism and 
lipoprotein, further corroborating the results of our analysis of the IGAP GWAS data. A list 
of the 151 genes is shown in Supplementary Table 11.
We also directly tested the modules described by Zhang et al.[21] for enrichment of 
association signal in the IGAP GWAS data (Supplementary Table 12). No single module 
was significantly enriched after correction for multiple testing of modules (“corr p” <0.05), 
but the most significantly enriched modules are immune-related. Interestingly, the immune/
microglia module highlighted by Zhang et al.[21] (#1, yellow) did not show significant 
enrichment for association signal in the IGAP GWAS under ALIGATOR analysis, although 
it did show moderate enrichment under GSEA. However, the 108 genes common both to 
this module and the set of 151 genes present in two or more of the four most significantly 
enriched modules in our analysis do show enrichment, which becomes progressively more 
significant as increasingly stringent criteria are used to select significant SNPs and genes 
(Supplementary Table 13). The genes that are in the Zhang module but not our set of 151 
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genes show no significant enrichment for association signal under either ALIGATOR or 
GSEA analysis.
Discussion
This analysis reveals pathways aetiologically related to AD in addition to those identified 
previously[14, 22]. The current sample[4] is larger than any used before and was imputed on 
a dense reference panel, giving improved gene coverage, and is therefore likely to be more 
powerful to detect real associations than any previous study. A larger set of pathways has 
been analysed than previously and annotations have changed, so gene membership of 
pathways is not identical to previous studies, though a substantial proportion of genes still 
fall into the annotation gap and are not currently mapped to any pathway. In the current 
analysis we also clustered genes that were within 1Mb of each other together in 
ALIGATOR, to prevent counting a single signal more than once. Secondary analyses were 
also performed removing genes in the APOE LD region and within 1Mb of the GWS genes. 
This was done to prevent pathway enrichments being biased by LD between pathway genes 
and neighbouring genes of strong effect, and to test whether there were significant pathway 
enrichments independent of “known” AD genes. Such enrichments would increase the 
interest of novel pathways and genes highlighted by the main analysis Despite these 
differences, many of the pathways previously identified[14] show enrichment in the IGAP 
dataset (Supplementary Table 14). These include cholesterol transport, immunity and the 
synaptic transmission, cholinergic pathway, the latter being the target of the cholinesterase 
class of drugs widely used in AD.
We used both GWAS and expression data to detect functional pathways associated with AD. 
ALIGATOR analysis of combined IGAP-GWAS and replication samples highlights four 
main areas of biology: the immune response, regulation of endocytosis, cholesterol transport 
and protein ubiquitination. The immune response is particularly significant in the replication 
sample, even when GWS genes from the IGAP GWAS are excluded. The replication SNPs 
were not chosen for pathway membership and do not survey the genome randomly, so the 
lack of significance in some pathway clusters once the GWS genes are removed does not 
mean that there is no excess signal in these pathways: this may simply not have been 
measured. However these data indicate that further genes that are involved in the immune 
response are likely to be implicated in LOAD. Both regulation of endocytosis and 
cholesterol transport are functions also implicated by the genome-wide significant genes, 
while the immune response and protein ubiquitination contain fewer genome-wide 
significant signals[4]. The most significant signals in the GSEA analysis relate to the same 
biology but add some additional categories related to neurological biology including the 
synapse and neuronal projection development along with calcium-related signalling, not 
revealed by ALIGATOR. It is notable that these areas of biology are linked by common 
gene membership (Figure 1) and their interdependence may also be important in 
susceptibility to AD.
The additional immune response genes implicated in cluster 1 (Table 3) are plausible AD 
risk genes: CR2 encodes complement receptor 2 which is present on subsets of B-cells as is 
the GWS CR1. HLA-DQB1 is in the chromosome 6 HLA locus in common with several 
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GWS loci. INPP5D is genome-wide significant once replication analyses are taken into 
account[4]. As well as being annotated as having immune system activity, ADAM10 has 
been proposed as a candidate α-secretase that cleaves APP to prevent the production of β-
amyloid[23]. The protein ubiquitination cluster 5 (Table 3) includes two ATPase subunits of 
the 19S proteasome, PSMC3 and PSMC6, and three proteins involved in transcriptional 
control, POLR2E, SUPT4H1 and TAF6. CNN2, encoding calponin 2, thought to regulate the 
actin cytoskeleton[24] appears in the endocytosis cluster, though it can also regulate 
phagocytosis in macrophages[25]. The additional genes from GSEA include CHRNA2 
encoding the neuronal cholinergic receptor, nicotinic, alpha 2 and RAPSN, the receptor-
associated protein of the synapse, both of which appear in the synaptic transmission, 
cholinergic pathway (Supplementary Table 13). CAV1 encodes caveolin 1 which can 
interact with APOE[26] and is found in caveolae, areas of cholesterol-rich lipid raft involved 
in endocytosis. CACNA1D encodes the calcium channel, voltage-dependent, L type, alpha 
1D subunit, one of a series of alpha subunits that confer channel-specific properties, 
influences insulin secretion and is a risk gene for type 2 diabetes[27]. Finally, APP itself is 
highlighted in this analysis: it is annotated in both the synapse and neuronal clusters. Recent 
findings show that there is at least one rare protective coding variant in APP seen in late 
onset AD[28] and this signal may reflect this or other relatively rare variants.
Convergent evidence for the importance of the immune response in AD susceptibility was 
obtained by performing WGCNA on expression data from four brain regions. The four 
modules that were significantly enriched for association in the IGAP GWAS after multiple 
testing correction were all related to the immune response, and shared multiple genes in 
common: INPP5D is GWS[4] and was the only GWS gene found in these modules. The 
enrichment for association was driven by genes that occurred in two or more of these 
modules. None of the modules from Zhang et al.[21] was significantly enriched for genetic 
association after multiple testing correction, though the immune-related modules in their 
study gave the strongest signal. However, while the microglia module highlighted by Zhang 
et al.[21] did not show significant enrichment for association, the genes shared in common 
with our signficant expression modules did, highlighting the utility of using multiple 
expression datasets in generating biologically-meaningful modules. The TYROBP gene 
highlighted by Zhang et al. as an important causal regulator is also a hub gene in this 
network[29].
Regulation of endocytosis, cholesterol transport and ubiquitination were not strongly 
represented in our WGCNA modules, which may relate to the large size of the modules and 
the use only of brain gene expression. In addition, co-ordinated gene expression in brain 
may well reflect differences in distribution of specific cell types or sub-types[30]. The brain 
expression signatures we used came from non-neurologically compromised brains but it is 
likely that changes in microglial composition or fate in response to inflammation or 
infection in these subjects could propagate such co-ordinate changes in gene expression. 
TREM2 is one of the 151 genes that occur in two or more expression modules (Figure 2) 
and rare variants in TREM2 are associated with a significant increase in AD 
susceptibility[12]. TREM2 regulates the phenotype of microglia controlling their 
downstream activation to an inflammatory or phagocytotic fate, thought to promote or 
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inhibit AD pathogenesis respectively[31]. Thus the expression signature we detect through 
genome–wide association may also be a marker for changes in microglial phenotypes that 
act to enhance or inhibit the susceptibility of individuals to AD.
As the main motivation for genetic analysis of complex traits is to understand the biology of 
disease and inform the search for treatments, interpretation of genetic signals in a 
biologically meaningful way is essential. Pathway analyses that integrate multiple dense 
sources of data provide a means of starting to do this. Identifying strong susceptibility 
targets also highlights potential drug targets. While expression analyses alone can provide 
important clues about aetiology of disease, integrating them with genetic data which identify 
causative factors underlying susceptibility to disease ensures that the gene expression 
signatures revealed are related to disease aetiology rather than secondary effects, making the 
pathways highlighted by the analysis primary targets for therapy. This study implicates 
regulation of endocytosis and protein ubiquitination, in addition to cholesterol metabolism, 
as potential therapeutic targets in AD. It strongly reinforces the critical role of the immune 
system in conferring AD susceptibility: gaining a detailed mechanistic understanding of the 
events within the immune system that predispose to AD and investigating how to address 
these mechanisms should now be a priority for AD research.
Online Methods
IGAP meta-analysis data—The main dataset was reported by the International 
Genomics of Alzheimer's Project (IGAP) consortium[4] and consists in total of 17,008 cases 
and 37,646 controls. The full details of the samples and methods for conduct of the GWA 
studies are provided in the respective manuscripts[4, 8, 22, 37-39]. This sample of AD cases 
and controls comprises 4 data sets taken from genome-wide association studies performed 
by GERAD, EADI, CHARGE and ADGC[40].
Each of these datasets was imputed with Impute2 software using 1000 genomes data (release 
Dec2010) as a reference panel. In total 11,863,202 SNPs were included in the SNPs allelic 
association result file. To make our analysis as conservative as possible, we only included 
autosomal SNPs which passed stringent quality control criteria, i.e. we included only SNPs 
with minor allele frequencies (MAF) ≥0.01 and INFO score greater than or equal to 0.8 in 
each individual study, resulting in 7,055,881 with SNPs which are present in at least 40% of 
the AD cases and 40% of the controls in the analysis. We corrected all individual SNPs p-
values for genomic control (GC) λ=1.087. These SNPs are well imputed on a large 
proportion of the sample, which increases confidence in the accuracy of the association 
analysis upon which the pathway and gene-wide analyses are based.
Replication data—11,632 SNPs with p-values <10-3 in the IGAP meta-analysis were 
successfully genotyped in a replication sample comprising 8,492 cases and 11,392 controls 
(see primary IGAP manuscript[40] for more details).
Assignment of SNPs to genes—SNPs were assigned to genes if they were located 
within the genomic sequence lying between the start of the first and the end of the last exon 
of any transcript corresponding to that gene, as defined by NCBI. The chromosome and 
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location for all currently known human SNPs was taken from the dbSNP132 database, as 
was their assignment to genes (using build 37.1). In total, we retained 2,804,431 (39.7% of 
the total) SNPs which annotated 28,636 unique genes with 1-16,514 SNPs per gene. 
Pathway analyses were also performed using 10kb and 60kb windows around genes to 
assign SNPs to genes.
Assignment of genes to functional gene sets—Genes were assigned to a series of 
functional gene sets defined by five independent sources: 1) Gene ontology (GO) [41] 
(http://www.geneontology.org/; downloaded 11/6/2011), 2) Kyoto Encyclopedia of Genes 
and Genomes (KEGG) [42] (http://www.genome.jp/kegg/; downloaded 27/6/2011), 3) the 
“canonical pathways” collection from the Molecular Signatures Database v3.0 (MsigDB) 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp) accessed on 2/2/2011. We restricted 
our analysis to a total of 9,816 functional gene sets containing between 3 and 500 genes: 
8,888 in GO, 234 in KEGG and 694 in MsigDB.
Statistical analysis
Gene-wide significance—Gene-wide significance was calculated by combining single-
SNP p-values while controlling for LD and different number of marker's per gene using 
Brown's method[15] adopted for set-based analysis of genetic data[43].
ALIGATOR analysis—ALIGATOR was then used to test the list of gene-wide 
significance measures for enrichment within functional gene sets as previously described in 
Holmans et al.[13]. Unlike methods designed for gene-expression data (where there is 
typically only one measurement per gene), ALIGATOR corrects for variable numbers of 
SNPs per gene. ALIGATOR takes a list of significant SNPs and coverts this into a list of the 
genes in which these SNPs lie. Each gene is counted once regardless of how many 
significant SNPs it contains, thus eliminating the influence of linkage disequilibrium (LD) 
between SNPs within genes Replicate gene lists of the same length as the original are 
generated by randomly sampling SNPs (thus correcting for variable gene size). The lists are 
used to obtain p- values for enrichment for each gene set, to correct these for testing multiple 
non-independent gene sets, and to test whether the number of significantly enriched gene 
sets is higher than expected.
To minimise the possibility of multiple significant genes in a pathway that are close together 
reflecting the same association signal due to LD, we conservatively grouped significant 
genes that were <1Mb apart and located in the same functional gene set into one signal. To 
remove the possibility of a small gene set being deemed significantly enriched based on just 
one signal, we only classed gene sets as being enriched if they carried at least two signals
To assess the potential of any bias caused by LD with strong association signals that had 
been previously identified in these samples, we also performed ALIGATOR analysis after 
excluding three sets of genes: a) all genes within 1Mb of APOE (77 genes), b) all genes 
within 1 Mb of APOE and the 21 genes containing a SNP reaching genome-wide 
significance (p<5×10-8) in the IGAP meta-analysis (98 genes) c) all genes within 1Mb of 
APOE or any of the 21 genome-wide significant genes (552 genes). The same p-value 
criteria for defining significant SNPs are used for all these analyses.
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Definition of significant SNPs and genes for ALIGATOR—ALIGATOR requires 
that a set of significant SNPs are chosen to define the list of significant genes used to 
determine pathway enrichment [13]. As the genetic signal extends beyond the genome-wide 
significant genes (Supplementary Table 1), the p-value cut off used to select these SNPs 
should be fairly lax. For our primary analysis, we selected SNPs such that 5% of the genes 
would be deemed significant. When no gene window was used to assign SNPs to genes, this 
required 18,472 SNPs, with a p-value criterion for inclusion of 8.32×10-4. When a 10kb 
window was used to assign SNPs to genes, the SNP p-value criterion required to cover the 
top 5% of genes is reduced to 5.39×10-4, (14,385 SNPs) and using a 60kb window reduces 
the criterion still further, to 1.66×10-4 (7,807 SNPs). Supplementary Table 2 shows the 
number of significantly enriched pathways using each of these windows. It can be seen that 
using a 0kb window gives a more significant excess of enriched pathways than the 10kb or 
60kb windows. Thus, the 0kb window was used for all analyses presented in this paper. To 
ensure that the results of the ALIGATOR analyses are not dependent on the choice of p-
value criterion for defining significant genes, secondary analyses were performed using a 
range of p-value criteria.
Gene-set-enrichment (GSEA) analysis—As a further validation of the ALIGATOR 
results, and to show that the results of our analyses are not driven by the choice of p-value 
cut-off for defining significant genes, gene-set enrichment analysis (GSEA) was performed 
on the gene sets nominally-significant (p<0.05) in the ALIGATOR analyses using the 
method described in[44]. Rather than defining a list of significant genes, GSEA ranks all 
genes in order of a gene-wide association statistic, and tests whether the genes in a particular 
gene set have higher rank overall than would be expected by chance, weighted by the values 
of their gene-wide association statistic (thus giving more weight to significant genes). 
Following Wang and colleagues, in order to allow for varying numbers of SNPs per gene, 
the gene-wide statistic used was the Simes-corrected single-SNP p-value[45]. Since the 
GSEA method is known to be sensitive to very strongly associated genes, the analysis was 
performed removing all genes within 1Mb of APOE, and also the 21 genome-wide 
significant genes.
Clustering of significantly-enriched gene sets—To aid functional interpretation, 
gene sets significantly enriched in the ALIGATOR analysis were assigned to clusters 
according to the genes they contain. This was done as follows: For each pair of gene sets, an 
overlap measure K was defined as the number of genes in common to both sets divided by 
the number of genes in the smaller dataset. A gene set was assigned to a cluster if the 
average K between it and the gene sets already in the cluster was greater than 0.4. If it was 
not possible to assign a gene set to an existing cluster, a new cluster was started. This 
procedure was carried out recursively, in descending order of enrichment significance.
Pathway analysis of replication data—Pathway-wide evidence of association in these 
data was assessed by aggregating the p-values of all SNPs in the pathway using the method 
of Brown. This is a generalisation of Fisher's method for combining p-values in situations 
where the p-values are not independent, and was adapted to genetic association data by 
Moskvina et al. (2011)[43]. LD between SNPs was estimated using the December 2010 
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release of the 1000 Genomes data (the same release that was used to impute the data for the 
IGAP meta-analysis).
The pathways of interest contain several genes with very significant associations in the 
IGAP meta analysis that are also strongly associated in the replication study. Since the 
presence of such genes can give rise to a significant Brown p-value even in the absence of 
signal from the remainder of the pathway, the analysis of the replication data was repeated 
removing all SNPs from genes containing a genome-wide significant (p<5×10-8) SNP in the 
IGAP meta-analysis.
Effect of varying p-value criterion on pathway analysis—A significant excess of 
enriched pathways is still observed (Supplementary Table 3) when the p-value criterion for 
defining significant SNPs (and, thus, genes) is varied. Again, the significantly enriched 
pathways from Table 3 also show significant enrichment over a range of p-value criteria 
(Supplementary Table 4), thus giving extra confidence that the enrichments are genuine, and 
not an artefact of how the significant genes are defined. This is confirmed by observing that 
many of the significantly enriched pathways from the ALIGATOR analysis also have 
significant p-values in the GSEA analysis (Table 3 and Supplementary Table 4).
Replication of pathway analysis results—Further confirmation of pathway 
significance was gained from a replication sample in which a subset of SNPs from the main 
IGAP study (excluding the APOE region) were studied: these showed a significant 
enrichment of association signal in the pathways identified by the pathway analysis of the 
IGAP meta-analysis data. Pathway-wide Brown p-values derived from the replication data 
(see online methods) are given in Supplementary Table 4 for all 177 pathways enriched at 
p<0.01 in the original ALIGATOR analysis. Of these pathways, 119 have a Brown p<0.05 
when all SNPs in the pathway are included, and 97 have a Brown p<0.05 after removal of 
SNPs from genes with a genome-wide significant SNP in the IGAP meta-analysis. These are 
considerably higher than expected by chance, and indicate the presence of genuine AD risk 
variants in these pathways, even outside the “known” AD risk genes.
Genes containing a significant SNP (p<8.32×10-4) in the IGAP meta-analysis that are also 
nominally significant (gene-wide p<0.05) in the replication data are shown in Table 4 for the 
pathway clusters listed in Table 2. Gene-wide p-values for all genes containing a significant 
SNP (p<8.32×10-4) in the IGAP meta-analysis that lie in any of the 177 pathways enriched 
at p<0.01 in the ALIGATOR analysis are shown in Supplementary Table 5.
As a final test of whether SNPs that lie in pathways of interest are enriched for association 
signal in the replication data, a regression analysis of replication p-value on pathway 
membership was performed. Specifically, the 5297 replication SNPs that lay within gene 
boundaries were sorted in order of their IGAP meta-analysis p-value. The list was then 
pruned by removing SNPs within 100kb of a more significant SNP from the IGAP meta-
analysis. This left 730 SNPs. The pruning procedure was carried out to prevent the 
regression analyses being biased by clusters of neighbouring SNPs with similar p-values. Of 
these pruned and filtered SNPs 163 were in the 177 pathways enriched at p<0.01 in the 
ALIGATOR analysis and were found to have significantly lower p-values than the genic 
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SNPs not in the pathways (p=5.57×10-5). However, the ALIGATOR analysis preferentially 
selects pathways enriched for significant SNPs in the IGAP meta analysis and the IGAP 
meta analysis p-value is a highly significant predictor of replication p-value (p<2×10-16). 
While this shows that pathway SNPs are selected from genes that are likely to be true 
positives, in order to demonstrate an advantage of pathway membership (in terms of 
replication p-value) over and above that conferred by being significant in the IGAP meta-
analysis, a linear regression was carried out of –log(replication p) on –log(IGAP meta p) and 
pathway membership simultaneously. Pathway SNPs had significantly lower replication p-
values than non-pathway SNPs even after correcting for IGAP meta p-value (2-sided 
p=0.0237). This provides further evidence of the utility of pathway analysis in highlighting 
true positive signals.
Description of Gibbs expression data—The brain expression data are described in 
Gibbs et al.[16] and the GEO database reference for the dataset is GSE15745.
Description of WGCNA and derivation of co-expressed modules—Present/absent 
calls were made on the dataset by detection p-value. Any single probeset from a sample was 
designated absent with a p-value >0.1. If more than half the probesets in the dataset were 
absent, they were flagged for removal. In addition, a sample was removed if the number of 
missing probesets were above 2 standard deviations from the mean of the dataset. After 
removing probesets with over 50% absence, the remaining data was normalised. The 
influence of age and post-mortem interval (PMI) on the dataset was accounted for by 
performing regression according to these values and taking the residuals.
All arrays were separated by tissue type. Each tissue sample set was further assessed for 
outliers by hierarchical clustering. Any branch of arrays at the top of the dendrogram that 
contained less than 10% of the total number of arrays was removed so that the further 
analysis would not be charactersing these small sub-groups but focus on more global 
patterns of gene expression. This pruning was continued until each of the principal branches 
on the dendrogram contained over 10% of all arrays. The final sample numbers are given in 
Supplementary Table 15.
Weighted gene correlation network analysis was performed in the R environment using the 
WGCNA package[17] and performed separately on each tissue type. The dataset was 
collapsed so that multiple probes were reduced to single gene values based on gene 
annotation of the probesets obtained from Biomart. For duplicate probesets, the largest mean 
value for the sample was selected.
Soft-thresholding powers were selected by plotting a range of candidate powers against 
connectivity measures and observing the values where connectivity began to decrease. 
These all occurred between power values of 6 and 8 for the 4 tissue types. The modules 
were then created with this soft-threshold power (using a minimum module size of 20), and 
the component gene names of the modules extracted. The modules were then tested for 
enrichment for association signal in the IGAP GWAS as pathways in ALIGATOR using the 
same thresholds for defining significant SNPs (p<8.32×10-4) as previously.
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Research in Context
As the main motivation for genetic analysis of complex traits is to understand the biology 
of disease and inform the search for treatments, interpretation of genetic signals in a 
biologically meaningful way is essential. Pathway analyses that integrate multiple dense 
sources of data provide a means of starting to do this. Identifying strong susceptibility 
targets also highlights potential drug targets. While expression analyses alone can 
provide important clues about aetiology of disease, integrating them with genetic data 
which identify causative factors underlying susceptibility to disease ensures that the gene 
expression signatures revealed are related to disease aetiology rather than secondary 
effects, making the pathways highlighted by the analysis primary targets for therapy. This 
study implicates regulation of endocytosis and protein ubiquitination, in addition to 
cholesterol metabolism, as potential therapeutic targets in AD. It strongly reinforces the 
critical role of the immune system in conferring AD susceptibility: gaining a detailed 
mechanistic understanding of the events within the immune system that predispose to AD 
and investigating how to address these mechanisms should now be a priority for AD 
research.
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Figure 1. The pathways highlighted by ALIGATOR ontology analyses are related
The network was generated in ReVIGO[32] using gene ontology processes identified in 
ALIGATOR only. Bubble size (and label font size) reflects the frequency of the GO term in 
the GOA database, bubble colour reflects pathway p-value. Similar GO terms are linked by 
edges (lines) in the network where line width reflects the degree of similarity between 
pathways but line length is arbitrary. Strong relationships are revealed between negative 
regulation of endocytosis and cholesterol transport and many of the pathways are related to 
the immune response process.
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Figure 2. The immune response is enriched in gene co-expression modules from human brain
A Venn diagram indicating the number of genes in common across the four modules that 
were found to be significantly enriched in the IGAP GWAS using ALIGATOR after 
correcting for multiple testing. Each significant module originates from a different brain 
region as indicated here (Cb = cerebellum, FC = frontal cortex, TC = temporal cortex). B 
Network showing the pathways significantly enriched for gene membership among the 151 
genes present in at least two of the four most significantly enriched expression modules: the 
principal biological themes were derived from DAVID[33-34] analysis. Terms from the 
analysis were filtered at 0.05% FDR, progressively clustered according to average gene 
similarity at a threshold of 90% and rendered on Cytoscape with the Enrichment Map 
plugin[35-36]. The diagram shows only the principal (lowest FDR) term for each of the 
clusters and white nodes indicate a single term that does not cluster with other groups. 
Coloured nodes indicate a multi-term cluster: the related terms represented by each node are 
given in C, in increasing significance order. Sources of the functional terms are:
BP = GOTERM_BP_FAT: Gene Ontology biological processes in DAVID's GO Fat 
Database;
CC = GOTERM_CC_FAT: Cellular Component terms in DAVID's GO Fat Database;
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SP = SP_PIR_KEYWORDS: keywords in the Uniprot (Swiss-Prot/Protein Information 
Resource) database
SEQ = UP_SEQ_FEATURE: Uniprot sequence annotation feature.
The full data are available in Supplementary Table 8
D Network showing the strongest correlations in expression (>0.9 in at least one brain area) 
between genes present in at least two of the four most significantly enriched expression 
modules.
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